

Economic Impact Analysis

The Department has determined that the regulation would not significantly affect the following:

- 1. The creation or elimination of jobs within the State of California.** The proposal may result in the creation of jobs but its extent cannot be estimated. It is unknown how many qualified researchers will utilize the California Biobank Program (CBP). The proposal should not result in the elimination of any existing jobs within the State.
- 2. The creation of new businesses or the elimination of existing businesses within the State of California.** The proposal may result in the creation of new businesses but its extent cannot be estimated. It is unknown how many individuals desiring to open biotech companies exist within the State of California. The proposal should not result in the elimination of any existing businesses.
- 3. The expansion of businesses currently doing business within the State of California.** The proposal may result in the expansion of businesses currently doing business with the State of California but its extent cannot be estimated. It is unknown how many businesses may expand due to testing resulting from researchers obtaining biospecimens and/or data from the CBP within the State of California.
- 4. The benefits of the regulation to the health and welfare of California residents, worker safety, and the state's environment.** The proposal may significantly increase the benefits to the health and welfare of California residents because it will develop protocols for the release of biospecimens and/or data to approved researchers for the development of diagnosis and treatment of medical disorders. The proposal would not significantly affect worker safety in the State of California. It will not require regulated activities in the work place. The proposal would not affect the state's environment. The release of biospecimens and/or data does not pose any known environmental hazards.

Significant Statewide Adverse Economic Impact Directly Affecting Business, Including Ability to Compete

The requirement that biospecimens and data be made available to researchers will have no significant adverse economic impact on any business. There are no private companies, at this time, that have access to the number and types of biospecimens and associated data that are contained within the CDPH/GDSP Biobank Program's repository. Thus, there will be no significant adverse economic impact on California businesses.

Local Mandate

The Department has determined that the regulation would not impose a mandate on local agencies or school districts, nor are there any costs for which reimbursement is

required by part 7 (commencing with Section 17500) of division 4 of the Government Code.

Effect on Small Business

The Department has determined that only those universities, research foundations, biotech companies, and non-profit organizations who choose to request and pay fees for biospecimens/and or data will be impacted. Only those small businesses that choose to make a request will be impacted. The cost will be determined by the type and quantity of biospecimens and/or data that the approved researcher requests.